FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)

Yukimasa Hatachi; Sharad R Mohan; Takeshi Kotake; Hironaga Satake; Yoshihiro Okita; Hisateru Yasui; Akihito Tsuji

doi:10.21873/cdp.10083

FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)

Cancer Diagn Progn. 2022 Jan 3;2(1):101-106. doi: 10.21873/cdp.10083. eCollection 2022 Jan-Feb.

Authors

Yukimasa Hatachi^{1

2}, Sharad R Mohan³, Takeshi Kotake^{1

4}, Hironaga Satake^{1

5}, Yoshihiro Okita^{1

6}, Hisateru Yasui¹, Akihito Tsuji^{1

6}

Affiliations

¹ Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
² Department of Clinical Oncology, Kansai Rosai Hospital, Amagasaki, Japan.
³ Department of Artificial Intelligence, AI Medical and Health Tech Systems, Osaka, Japan.
⁴ Department of Clinical Oncology, Kansai Electric Power Hospital, Osaka, Japan.
⁵ Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan.
⁶ Department of Clinical Oncology, Kagawa University Hospital, Kagawa, Japan.

Abstract

Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.

Patients and methods: Patients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities.

Results: Patients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months.

Conclusion: The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m ² , irinotecan 180 mg/m ² , l-leucovorin 400 mg/m ² and 5-FU 2,400 mg/m ² , administered as a continuous 46-h infusion.

Keywords: FOLFIRINOX; dose limiting toxicity; optimal dose; pancreatic cancer.